Ellsworth Advisors LLC Takes $670,000 Position in Theravance Biopharma, Inc. $TBPH

Ellsworth Advisors LLC bought a new position in Theravance Biopharma, Inc. (NASDAQ:TBPH) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 33,332 shares of the biopharmaceutical company’s stock, valued at approximately $670,000. Ellsworth Advisors LLC owned 0.07% of Theravance Biopharma as of its most recent filing with the SEC.

A number of other institutional investors have also bought and sold shares of TBPH. Quarry LP bought a new stake in Theravance Biopharma during the third quarter valued at about $26,000. Caitong International Asset Management Co. Ltd boosted its stake in shares of Theravance Biopharma by 107.4% in the third quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 1,411 shares during the period. Tower Research Capital LLC TRC grew its position in shares of Theravance Biopharma by 18.5% during the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 781 shares in the last quarter. CIBC Private Wealth Group LLC grew its position in shares of Theravance Biopharma by 20,269.6% during the third quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock worth $68,000 after purchasing an additional 4,662 shares in the last quarter. Finally, SG Americas Securities LLC bought a new stake in Theravance Biopharma during the 3rd quarter valued at approximately $101,000. Hedge funds and other institutional investors own 99.10% of the company’s stock.

Insider Buying and Selling at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 31,067 shares of the firm’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $13.96, for a total value of $433,695.32. Following the completion of the transaction, the senior vice president directly owned 232,699 shares of the company’s stock, valued at approximately $3,248,478.04. This trade represents a 11.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 6.90% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. TD Cowen boosted their price target on Theravance Biopharma from $13.00 to $15.00 and gave the stock a “hold” rating in a report on Monday, March 23rd. Wall Street Zen upgraded shares of Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a research report on Sunday, March 29th. BTIG Research reissued a “buy” rating and issued a $21.00 target price on shares of Theravance Biopharma in a report on Friday, March 20th. Weiss Ratings upgraded shares of Theravance Biopharma from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, March 24th. Finally, B. Riley Financial reaffirmed a “neutral” rating and set a $14.00 target price (down from $28.00) on shares of Theravance Biopharma in a research note on Wednesday, March 4th. Two research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $21.33.

Theravance Biopharma Trading Up 1.1%

Shares of Theravance Biopharma stock opened at $16.02 on Friday. The firm has a market cap of $824.87 million, a PE ratio of 7.89 and a beta of 0.17. The stock has a 50 day moving average of $17.13 and a 200 day moving average of $16.94. Theravance Biopharma, Inc. has a 12 month low of $7.90 and a 12 month high of $21.03.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.